作者
Nanja van Geel,Reinhart Speeckaert,Alain Taı̈eb,Khaled Ezzedine,Henry W. Lim,Amit G. Pandya,Thierry Passeron,Albert Wolkerstorfer,Marwa Abdallah,Augustín Alomar,Jung Min Bae,Marcel W. Bekkenk,Laïla Benzekri,Markus Böhm,Viktoria Eleftheriadou,Samia Esmat,Deepti Ghia,Boon Kee Goh,Pearl E. Grimes,Somesh Gupta,Iltefat Hamzavi,John E. Harris,Sang Ho Oh,Richard H. Huggins,Ichiro Katayama,Eric Lan,Ai‐Young Lee,Giovanni Leone,Caroline Le Poole,Harvey Lui,Nicolle Maquignon,Jean Marie Meurant,Paul Monteiro,Naoki Oiso,Davinder Parsad,Georg Pliszewski,Noufal Raboobee,Michelle Rodrigues,David Rosmarin,Tamio Suzuki,Atsushi Tanemura,Steven Tien Guan Thng,Flora Xiang,Youwen Zhou,Mauro Picardo,Julien Sénéschal
摘要
The treatment of vitiligo can be challenging and depends on several factors such as the subtype, disease activity, vitiligo extent, and treatment goals. Vitiligo usually requires a long-term approach. To improve the management of vitiligo worldwide, a clear and up-to-date guide based on international consensus with uniform stepwise recommendations is needed.To reach an international consensus on the nomenclature and to develop a management algorithm for the diagnosis, assessment, and treatment of vitiligo.In this consensus statement, a consortium of 42 international vitiligo experts and four patient representatives participated in online and live meetings to develop a consensus management strategy for vitiligo. At least two vitiligo experts summarized the evidence of topics included in the algorithms. A survey was utilized to resolve remaining issues among a core group of eight experts. Subsequently, the unanimous recommendations were finalized and validated based on further input from the entire group during two live meetings.The algorithms highlight the importance of shared decision-making. Dermatologists are encouraged to provide patients with detailed explanations of the prognosis and expected therapeutic outcomes based on clinical examination. The treatment goal should be discussed and clearly emphasized to patients given the different approaches for disease stabilization and repigmentation. The evaluation of disease activity remains a cornerstone in the tailor-made approach to vitiligo patients.These new treatment algorithms are intended to guide clinical decision-making in clinical practice. Promising novel therapies for vitiligo are on the horizon, further highlighting the need for reliable outcome measurement instruments and greater emphasis on shared decision-making.